Crinetics Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
On August 3, 2026, Crinetics Pharmaceuticals, Inc. announced and furnished a press release reporting its financial results for the period ended June 30, 2026. The full press release is attached to the Current Report on Form 8-K as Exhibit 99.1. The filing was signed by President and CEO R. Scott Struthers, Ph.D. The company expressly notes the press release is "furnished" under Form 8-K General Instruction B.2 and therefore is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act and is not automatically incorporated by reference into other filings.

Key Details

• Date of 8-K filing and press release: August 3, 2026.
• Reporting period: financial results for the period ended June 30, 2026.
• Exhibit included: Press Release (Exhibit 99.1) and Inline XBRL cover page (Exhibit 104).
• Signed by: R. Scott Struthers, Ph.D., President and Chief Executive Officer.

Why It Matters
This 8-K informs investors that Crinetics has publicly reported its quarterly financial results and related commentary; investors should read the attached press release (Exhibit 99.1) for revenue, expense, cash position, and any program or clinical updates that could affect the stock. Note the company’s statement that the release is furnished (not filed), which limits certain legal liabilities and means the content isn’t automatically incorporated by reference into other SEC filings.